Studies on the metabolism and biological activity of the epimers of sulindac

Drug Metabolism and Disposition

Volumn 39, Issue 6, 2011, Pages 1014-1021

  Brunell, David ^a   Sagher, Daphna ^a   Kesaraju, Shailaja ^a   Brot, Nathan ^a   Weissbach, Herbert ^a  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; METHIONINE SULFOXIDE REDUCTASE B; OXIDOREDUCTASE; SULINDAC; SULINDAC REDUCTASE; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN TISSUE; CATALYSIS; CELL PROTECTION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME PURIFICATION; ENZYME SPECIFICITY; EPIMER; HUMAN; HUMAN CELL; LIVER MICROSOME; LIVER PARENCHYMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SKIN;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ESCHERICHIA COLI; HEP G2 CELLS; HUMANS; METHIONINE SULFOXIDE REDUCTASES; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; SULINDAC;

EID: 79956123093     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037663     Document Type: Article

References (32)

1. Ciolino HP, Bass SE, MacDonald CJ, Cheng RY, and Yeh GC (2008) Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer 122:990-998. (Pubitemid 351213995)
2. Ciolino HP, MacDonald CJ, Memon OS, Bass SE, and Yeh GC (2006) Sulindac regulates the aryl hydrocarbon receptor-mediated expression of phase 1 metabolic enzymes in vivo and in vitro. Carcinogenesis 27:1586-1592. (Pubitemid 44288047)
3. Duggan DE, Hooke KF, Risley EA, Shen TY, and Arman CG (1977) Identification of the biologically active form of sulindac. J Pharmacol Exp Ther 201:8-13. (Pubitemid 8085991)
4. Etienne F, Resnick L, Sagher D, Brot N, and Weissbach H (2003) Reduction of sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system. Biochem Biophys Res Commun 312:1005-1010. (Pubitemid 37490915)
5. Grimaud R, Ezraty B, Mitchell JK, Lafitte D, Briand C, Derrick PJ, and Barras F (2001) Repair of oxidized proteins. Identification of a new methionine sulfoxide reductase. J Biol Chem 276:48915-48920.
6. Gwyn K and Sinicrope FA (2002) Chemoprevention of colorectal cancer. Am J Gastroenterol 97:13-21. (Pubitemid 34059758)
7. Hamman MA, Haehner-Daniels BD, Wrighton SA, Rettie AE, and Hall SD (2000) Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem Pharmacol 60:7-17. (Pubitemid 30243080)
8. Hixson LJ, Alberts DS, Krutzsch M, Einsphar J, Brendel K, Gross PH, Paranka NS, Baier M, Emerson S, and Pamukcu R (1994) Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 3:433-438. (Pubitemid 24221454)
9. Huskisson EC and Scott J (1978) Sulindac. Trials of a new anti-inflammatory drug. Ann Rheum Dis 37:89-92. (Pubitemid 8371834)
10. Kim HY and Gladyshev VN (2004) Methionine sulfoxide reduction in mammals: characterization of methionine-R-sulfoxide reductases. Mol Biol Cell 15:1055-1064.
11. Kitamura S and Tatsumi K (1982) In vitro metabolism of sulindac and sulindac sulfide: enzymatic formation of sulfoxide and sulfone. Jpn J Pharmacol 32:833-838. (Pubitemid 12030630)
12. Lowther WT, Weissbach H, Etienne F, Brot N, and Matthews BW (2002) The mirrored methionine sulfoxide reductases of Neisseria gonorrhoeae pilB. Nat Struct Biol 9:348-352. (Pubitemid 34462552)
13. Marchetti M, Resnick L, Gamliel E, Kesaraju S, Weissbach H, and Binninger D (2009) Sulindac enhances the killing of cancer cells exposed to oxidative stress. PloS ONE 4:e5804.
14. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al. (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1:32-38.
15. Minetti G, Balduini C, and Brovelli A (1994) A reduction of DABS-L-methionine-dl-sulfoxide by protein methionine sulfoxide reductase from polymorphonuclear leukocytes: stereospecificity towards the L-sulfoxide. Ital J Biochem 43:273-283.
16. Moench I, Prentice H, Rickaway Z, and Weissbach H (2009) Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms. Proc Natl Acad Sci USA 106:19611-19616.
17. Moskovitz J, Berlett BS, Poston JM, and Stadtman ER (1997) The yeast peptide-methionine sulfoxide reductase functions as an antioxidant in vivo. Proc Natl Acad Sci USA 94:9585-9589. (Pubitemid 27408105)
18. Moskovitz J, Singh VK, Requena J, Wilkinson BJ, Jayaswal RK, and Stadtman ER (2002) Purification and characterization of methionine sulfoxide reductases from mouse and Staphylococcus aureus and their substrate stereospecificity. Biochem Biophys Res Commun 290:62-65. (Pubitemid 34694464)
19. Moskovitz J, Weissbach H, and Brot N (1996) Cloning the expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins. Proc Natl Acad Sci USA 93:2095-2099. (Pubitemid 26079886)
20. Pangburn HA, Ahnen DJ, and Rice PL (2010) Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor. Cancer Prev Res (Phila) 3:560-572.
21. Park JH, Kim EJ, Jang HY, Shim H, Lee KK, Jo HJ, Kim HJ, Yang SH, Jeong ET, and Kim HR (2008) Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep 20:379-384.
22. Rahman MA, Nelson H, Weissbach H, and Brot N (1992) Cloning, sequencing, and expression of the Escherichia coli peptide methionine sulfoxide reductase gene. J Biol Chem 267:15549-15551.
23. Ratnayake JH, Hanna PE, Anders MW, and Duggan DE (1981) Sulfoxide reduction. In vitro reduction of sulindac by rat hepatic cytosolic enzymes. Drug Metab Dispos 9:85-87. (Pubitemid 11150854)
24. Resnick L, Rabinovitz H, Binninger D, Marchetti M, and Weissbach H (2009) Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses. J Drugs Dermatol 8:29-32.
25. Sagher D, Brunell D, Brot N, Vallee BL, and Weissbach H (2006a) Selenocompounds can serve as oxidoreductants with the methionine sulfoxide reductase enzymes. J Biol Chem 281:31184-31187. (Pubitemid 46041383)
26. Sagher D, Brunell D, Hejtmancik JF, Kantorow M, Brot N, and Weissbach H (2006b) Thionein can serve as a reducing agent for the methionine sulfoxide reductases. Proc Natl Acad Sci USA 103:8656-8661. (Pubitemid 43878076)
27. Seo SK, Jin HO, Lee HC, Woo SH, Kim ES, Yoo DH, Lee SJ, An S, Rhee CH, Hong SI, et al. (2008) Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol Pharmacol 73:1005-1012.
28. Sharov VS, Ferrington DA, Squier TC, and Schöneich C (1999) Diastereoselective reduction of protein-bound methionine sulfoxide by methionine sulfoxide reductase. FEBS Lett 455:247-250. (Pubitemid 29333045)
29. Taketo MM (1998a) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90:1529-1536.
30. Taketo MM (1998b) Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90:1609-1620.
31. Van Arman CG, Risley EA, Nuss GW, Mucker HB, and Duggan DE (1976) Pharmacology of sulindac, in Clinoril in The Treatment of Rheumatic Disorders (Huskisson EC and Franchimont P eds), pp 9-36, Raven Press, New York.
32. Weissbach H, Resnick L, and Brot N (2005) Methionine sulfoxide reductases: history and cellular role in protecting against oxidative damage. Biochim Biophys Acta 1703:203-212. (Pubitemid 40170443)